Table 1 Baseline characteristics
Characteristic | 60 mg (n = 12) | 200 mg (n = 12) | 400 mg (n = 12) | Total (n = 36) |
|---|---|---|---|---|
Age, years | ||||
Median | 52 | 54.5 | 58.5 | 56 |
Range | 35–66 | 35–65 | 35–65 | 35–66 |
Gender, no. (%) | ||||
Male | 8 (66.7%) | 10 (83.3%) | 10 (83.3%) | 28 (77.8%) |
Female | 4 (33.3%) | 2 (16.7%) | 2 (16.7%) | 8 (22.2%) |
ECOG PS, no. (%) | ||||
0 | 10 (83.3%) | 11 (91.7%) | 10 (83.3%) | 31 (86.1%) |
1 | 2 (16.7%) | 1 (8.3%) | 2 (16.7%) | 5 (13.9%) |
Tumour type, no. (%) | ||||
Oesophageal squamous cell carcinoma | 3 (25.0%) | 9 (75.0%) | 2 (16.7%) | 14 (38.9%) |
Gastric cancer | 3 (25.0%) | 0 | 2 (16.7%) | 5 (13.9%) |
Triple-negative breast cancer | 2 (16.7%) | 1 (8.3%) | 1 (8.3%) | 4 (11.1%) |
Colorectal cancer | 0 | 1 (8.3%) | 2 (16.7%) | 3 (8.3%) |
Non-small-cell lung cancer | 2 (16.7%) | 0 | 1 (8.3%) | 3 (8.3%) |
Nasopharyngeal cancer | 2 (16.7%) | 0 | 1 (8.3%) | 3 (8.3%) |
Hepatocellular carcinoma | 0 | 0 | 2 (16.7%) | 2 (5.6%) |
Bladder cancer | 0 | 0 | 1 (8.3%) | 1 (2.8%) |
Cervical cancer | 0 | 1 (8.3%) | 0 | 1 (2.8%) |
Previous treatment, no. (%) | ||||
Surgery | 7 (58.3%) | 6 (50.0%) | 9 (75.0%) | 22 (61.1%) |
Radiotherapy | 7 (58.3%) | 8 (66.7%) | 3 (25.0%) | 18 (50.0%) |
Chemotherapy | 12 (100.0%) | 12 (100.0%) | 12 (100.0%) | 36 (100.0%) |
Lines of previous chemotherapy, no. (%) | ||||
1 | 1 (8.3%) | 3 (25.0%) | 4 (33.3%) | 8 (22.2%) |
2 | 4 (33.3%) | 5 (41.6%) | 5 (41.6%) | 14 (38.9%) |
3 | 3 (25.0%) | 2 (16.7%) | 2 (16.7%) | 7 (19.4%) |
4 | 4 (33.3%) | 2 (16.7%) | 1 (8.3%) | 7 (19.4%) |
